Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:44 2024-05-03 am EDT			5-day change	1st Jan Change
87.97 ^CHF	-1.01%		-1.71%	+3.65%

May. 02	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ
May. 02	Sector Update: Health Care Stocks Softer Late Afternoon	MT

NOVARTIS AG : JP Morgan remains Neutral

April 24, 2024 at 03:26 am EDT

Analyst Sandeep Deshpande from JP Morgan research gives the stock a Neutral rating. The target price has been raised to CHF 95 from CHF 90.

Latest news about Novartis AG

Health Care Flat Amid Mixed Earnings -- Health Care Roundup	May. 02	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	May. 02	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	May. 02	MT
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat	May. 02	MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	May. 02	DJ
Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion.	May. 02	MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	May. 02	DJ
Novartis: acquisition of US-based Mariana Oncology	May. 02	CF
Switzerland's Novartis to Buy US-based Mariana Oncology for $1 Billion Upfront	May. 02	MT
Novartis to Buy Mariana Oncology, Pay $1 Billion Upfront	May. 02	MT
Novartis AG to Acquire Mariana Oncology	May. 02	MT
Novartis AG to Acquire Mariana Oncology	May. 02	MT
Novartis to Buy Mariana Oncology for Up to $1.75 Billion in Boost to Radioligand Therapy Business	May. 02	DJ
Novartis to buy radiology specialist Mariana Oncology for $1 billion	May. 02	RE
Chimeric Therapeutics Appoints COO; Shares Rise 4%	May. 01	MT
Novartis AG entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.	May. 01	CI
Avacta picks Christina Coughlin to replace long-serving CEO	May. 01	AN
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	Apr. 30	CI
Novartis target Morphosys multiplies losses - takeover schedule stands	Apr. 29	DP
Morphosys says takeover by Novartis on course after report of drug safety concern	Apr. 29	RE
NOVARTIS AG : Receives a Buy rating from Jefferies	Apr. 26	ZD
BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	Apr. 24	MT

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-05-22 - Deutsche Bank dbAccess European Champions Conference

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

97.24 USD

Average target price

108.4 USD

Spread / Average Target

+11.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+3.65%	198B
ELI LILLY AND COMPANY	+26.08%	662B
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

NOVARTIS AG : JP Morgan remains Neutral

Latest news about Novartis AG

Chart Novartis AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novartis AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals